glp 1 coverage Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss What You Need to Know

The world of obesity treatment has been transformed by the groundbreaking discovery and development of GLP-1-based drugs

sitagliptin 50 mg bid with metformin 500 mg bid, -1.6%

Gambero A, Ribeiro ML

Current head-to-head evidence suggests tirzepatide may produce greater average weight loss than semaglutide

Small-scale clinical trials revealed that GLP-1 and GLP-1-based medicines may have positive effects on low-grade inflammation, blood pressure, cholesterol, and microcirculation ( Due to their various modes of action, which include vasodilation, natriuresis, glucose and weight control, and direct cardioprotective effects, GLP-1 receptor agonists have therapeutic potential for treatment of heart failure ( Obesity is a major cause of cardiovascular diseases